SALT score distribution with ritlecitinib treatment up to 24 months in alopecia areata

Documenti analoghi

• Long‐term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO‐LT phase 3, open‐label study
  di: C. Tziotzios, et al.
  Pubblicazione: (2025)
• Baricitinib and low‐dose prednisone for very severe alopecia areata: A retrospective case series
  di: Karen Aouar, et al.
  Pubblicazione: (2026)
• Real‐world efficacy and safety of ritlecitinib in alopecia areata: A single‐centre experience
  di: Youyu Sheng, et al.
  Pubblicazione: (2025)
• Alopecia areata and ritlecitinib: Unravelling response trajectories
  di: Julien Seneschal
  Pubblicazione: (2025)
• Strong efficacy of ritlecitinib 50 mg and baricitinib 4 mg in alopecia areata, but further research needed to establish superiority
  di: David Saceda‐Corralo, et al.
  Pubblicazione: (2025)